Kymera Therapeutics Inc (KYMR)
32.11
-0.05
(-0.16%)
USD |
NASDAQ |
May 31, 16:00
32.10
-0.02
(-0.05%)
After-Hours: 20:00
Kymera Therapeutics Net Income (Quarterly): -48.56M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -48.56M |
December 31, 2023 | -14.37M |
September 30, 2023 | -52.87M |
June 30, 2023 | -38.80M |
March 31, 2023 | -40.93M |
December 31, 2022 | -34.86M |
September 30, 2022 | -43.00M |
June 30, 2022 | -40.26M |
March 31, 2022 | -36.68M |
December 31, 2021 | -33.90M |
Date | Value |
---|---|
September 30, 2021 | -28.58M |
June 30, 2021 | -24.66M |
March 31, 2021 | -13.08M |
December 31, 2020 | -12.68M |
September 30, 2020 | -7.986M |
June 30, 2020 | -13.99M |
March 31, 2020 | -10.93M |
December 31, 2019 | -11.51M |
September 30, 2019 | -11.42M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-52.87M
Minimum
Sep 2023
-7.986M
Maximum
Sep 2020
-27.32M
Average
-28.58M
Median
Sep 2021
Net Income (Quarterly) Benchmarks
SELLAS Life Sciences Group Inc | -9.566M |
Iovance Biotherapeutics Inc | -112.98M |
Immunic Inc | -29.58M |
Protagonist Therapeutics Inc | 207.34M |
Ovid Therapeutics Inc | -11.69M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 10.29M |
Total Expenses (Quarterly) | 63.19M |
EPS Diluted (Quarterly) | -0.69 |
Enterprise Value | 1.450B |
Profit Margin (Quarterly) | -472.0% |
Earnings Yield | -7.82% |
Normalized Earnings Yield | -7.600 |